TARS supply chain intelligence for Tarsus Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Tarsus Pharmaceuticals, Inc. (TARS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LIMITED-SPECIALTY-PHARMACIES | LIMITED-SPECIALTY-PHARMACIES | 90% | The Company periodically enters into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. |
| XI-AN-GRAND-CHANG-AN-PHARMACEUTICAL-CO-LTD | XI-AN-GRAND-CHANG-AN-PHARMACEUTICAL-CO-LTD | 85% | in China for the treatment of Demodex blepharitis and Meibomian Gland Disease (“MGD”) to Xi An Grand Chang An Pharmaceutical Co., Ltd. (“GrandPharma”). Revenue is recognized in proportion to the allo… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | debt financings, or collaborations, strategic alliances, or licensing arrangements with third parties. Adequate funding may not be available to us when needed on acceptable terms, or at all. If we ra… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | by new guidance and/or judicial/regulatory interpretations, which could entail further impacts on our compliance efforts and increased cost. Failure to comply with U.S. and international data protect… |
| ELAN | Elanco Animal Health Incorporated | 62% | Reciprocal relationship from ELAN graph: Reciprocal relationship from TARS graph: Reciprocal relationship from ELAN graph: Reciprocal relationship from TARS graph: Reciprocal relationship from ELAN g… |
| ELANCO-TIERGESUNDHEIT-AG | ELANCO-TIERGESUNDHEIT-AG | 62% | ation of our product or our product candidates, including XDEMVY for the treatment of Demodex blepharitis, TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease pro… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TARS-DEBT-12882 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| TARS-DEBT | Debt stack $72.8M | 90% | Market cache reports total debt of $72.8M. |
| TARS-DEBT-12881 | Warrants outstanding: 312500 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TARS-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 256 tracked holders. |